Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-08-09
2005-08-09
Nguyen, Dave Trong (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093210, C424S424000, C435S178000, C435S182000, C435S325000, C435S375000
Reexamination Certificate
active
06926888
ABSTRACT:
Encapsulated producer cells which are capable of expressing a molecule which is an inhibitor of CNS tumour growth provide a novel approach to the treatment of tumours, such as brain tumors which are localized within the central nervous system.
REFERENCES:
patent: 5166137 (1992-11-01), Otterlei et al.
patent: 5459054 (1995-10-01), Skjak-Braek et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 92/19195 (1992-11-01), None
patent: 96/01611 (1996-01-01), None
patent: 96/28029 (1996-09-01), None
patent: 97/36495 (1997-10-01), None
patent: 97/38707 (1997-10-01), None
patent: 97/44065 (1997-11-01), None
T Visted et al., Neuro-Oncology, “Cell encapsulation technology as a therapeutic strategy for CNS malignancies,” Jul. 2001, pp. 201-210.
MS O'Reilly et al.,Cell,“Endostatin:An Endogenous Inhibtor of Angiogenesis and Tumor Growth,” Jan. 1997, vol. 88, pp. 277-285.
Skjåk-Braek and Espevik, “Application of alginate gels in biotechnology and biomedicine,”Carbohydrates in Europe, vol. 14, pp. 19-25, 1996.
Kulseng et al., “Alginate polylysine microcapsules as immune barrier: Permeability of cytokines and immunoglobulins over the capsule membrane,”Cell Transplantation, vol. 6, pp. 387-394, 1997.
Smidsrød and Draget, “Chemistry and physical properties of alginate,”Carbohydrates in Europe, 14, 6-13, 1996.
Read, T.-A. et al., “Cells Encapsulated in Alginate: A Potential System for Delivery of Recombinant Proteins to Malignant Brain Tumours,” Int. J. Dev. Neuroscience, vol. 17, No. 5-6, pp. 653-663, 1999.
Lund, E.L. et al., “Tumor Angiogenesis—A New Therapeutic Target in Gliomas,” Acta Neurol. Scand., vol. 97, No. 1, pp. 52-62, 1998. (Abstract only).
Yin, D.X. et al., “Tetracycline-controlled Gene Expression System Achieves High-lev I and Quantitative Control of Gene Expression,” Anal. Biochem., vol. 235, No. 2, pp. 195-201, 1996. (Abstract only).
Otterlei, M. et al., “Induction of Cytokine Production From Human Monocytes Stimulated With Alginate,” J. Immunother., vol. 10, No. 4, p. 286-291. (Abstract only).
Avalosse, B. et al., “Gene Therapy for Cancer”, Curr. Opin. Oncol., vol. 7, pp. 94-100, 1995.
Gordon, Erlinda M. et al., “Gene Therapy Using Retroviral Vectors”, Curr. Opin. Biotechnol, vol. 5, pp. 611-616, 1994.
Steele, Cherrilee et al., “Effects of Human Papillomavirus Type 18-specific Antisense Oligonucleotides on the Transformed Phenotype of Human Carcinoma Cell Lines”, Cancer Res., vol. 53, No. 10 pp. 2330-2337, 1993.
Zhang, Y. et al., “Retroviral Vector-Mediated Transduction of K-ras Antisense RNA into Human Lung Cancer Cells Inhibits Expression of the Malignant Phenotype”, Hum. Gen Ther., vol. 4, pp. 451-460, 1993.
Tepper, Robert I. et al., “Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells”, Hum. Gene Ther., vol. 5, pp. 153-164, 1994.
Pardoll, Drew M., “Cancer Vaccines”, Trends Pharmacol. Sci., vol. 14, pp. 202-208, 1993.
Smidsrød and Skjak-Braek, “Alginate as Immobilization Matrix for Cells,” Trends in Biotechnology, vol. 8, pp. 71-78, 1990.
Laerum, O.D. et al., “Neoplastic Transformation of Fetal Rat Brain Cells in Culture Aft r Exposure to Ethylnitrosourea In Vivo”, J. Natl. Cancer Inst., vol. 55, No. 5, pp. 1177-1187, 1975.
Thorsen, F. et al., “Release of Replication-Deficient Retroviruses From a Packaging Cell Line: Interaction with Glioma Tumor Spheroids in Vitro”, Intl. J. Cancer, vol. 71, No. 5, pp. 874-880, 1997.
Anderson, M.L.M. et al., “Onco-Suppressor Genes and Their Involvement in Cancer”, Anticancer Research, vol. 8, No. 5A, pp. 873-879, 1988.
Kim et al., “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer”, Science, vol. 266, pp. 2011-2015, 1994.
Lund-Johansen, M. et al., “Effects of Growth Factors on a Human Glioma Cell Line During Invasion Into Rat Brain Aggregates in Cultur”, Acta Neuropathol., vol. 84, No. 2, pp. 190-197, 1992.
Baisch, H. et al., “Analysis of PCP-Data to Determine the Fraction of Cells in the Various Phases of Cell Cycle”, Radiat. Environ. Biophys., vol. 12, No. 1, pp. 31-39, 1975.
Soon-Shiong, P. et al., “Successful Reversal of Spontaneous Diabetes in Dogs by Intraperitoneal Microencapsulated Islets”, Transplantation, vol. 54, No. 5, pp. 769-774, 1992.
Angell Jon Eric
FMC Biopolymer AS
Nguyen Dave Trong
Woodcock & Washburn LLP
LandOfFree
Alginate capsules for use in the treatment of brain tumor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alginate capsules for use in the treatment of brain tumor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alginate capsules for use in the treatment of brain tumor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3491508